Trial Profile
A Phase II Study of Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma and Melanomas That Arise on Chronically Sun Damaged Skin.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Acral lentiginous melanoma; Malignant melanoma
- Focus Therapeutic Use
- Acronyms BUS255
- 16 Oct 2016 Status changed from active, no longer recruiting to completed.
- 19 Jan 2016 Planned End Date changed from 1 Oct 2014 to 1 Aug 2016 as per ClinicalTrials.gov record.
- 24 Feb 2014 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.